Skip to content
Laxxon Medical

Laxxon Medical

Company

As of November 2026

Laxxon Medical Corp. is a privately held drug development company with headquarters in New York and research and development in Jena, Germany.

Leadership

  • Portrait of Helmut Kerschbaumer

    Helmut Kerschbaumer

    CEO and Chairman

    Helmut Kerschbaumer trained in retail distribution at C&A in Germany and went on to join the management board of C&A Austria.

  • Portrait of Klaus Kühne

    Klaus Kühne

    Chief Operating Officer

    Klaus Kühne is a lawyer with more than 25 years of experience in the pharmaceutical industry and expertise in managing product development, global commercialization, marketing and operations.

  • Portrait of Alexander Ruckdaeschel

    Alexander Ruckdaeschel

    Chief Strategy Officer

    Alexander Ruckdaeschel has worked in the financial industry in the United States and Europe since 2001, as a co-founder, partner and senior manager.

  • Portrait of Achim Schneeberger, MD

    Achim Schneeberger, MD

    Chief Scientific Officer

    Achim Schneeberger holds an MD from the University of Tübingen, Germany, and began his medical career at the Medical University of Vienna. He has more than 20 years of experience in biomedical research and drug development, with a focus on cancer and chronic diseases. After a research stay at Washington University in St. Louis, USA, he joined AFFiRiS AG, an Austrian vaccine developer.

Board of Directors

  • Portrait of Helmut Kerschbaumer

    Helmut Kerschbaumer

    Chairman

    See leadership →
  • Portrait of Klaus Kühne

    Klaus Kühne

    Director

    See leadership →
  • Portrait of Alexander Ruckdaeschel

    Alexander Ruckdaeschel

    Director

    See leadership →
  • Portrait of Achim Schneeberger, MD

    Achim Schneeberger, MD

    Director

    See leadership →
  • Portrait of Michael A. Stebler

    Michael A. Stebler

    Non-executive Director

    Read bio

    Michael A. Stebler has served on the Board of Directors of Laxxon Medical Corp. since 2026. He works closely with the CEO and the COO on corporate strategy.

    He brings more than 25 years of experience in senior management positions at Swisscom Mobile, Credit Suisse and UBS. He holds master's degrees from the University of Rochester and the University of Bern.

  • Nneka Ukpai

    Independent Non-executive Director

    Read bio

    Nneka Ukpai is a financial technology innovator working with Pop Venture to democratize access to private capital markets. She previously served as Head of Financial Innovation at Better, a homeownership platform that has surpassed $100 billion in funded volume.

    Before Better, she was a senior attorney at a global law firm, where she helped C-suite executives navigate global regulatory and enforcement actions. She is a graduate of Howard University and Harvard Law School, where she serves on the teaching faculty of the Trial Advocacy Workshop. Her focus on driving growth while mitigating business risk has made her a trusted advisor to CEOs and led her to serve on several private boards.

Scientific Advisory Board

  • Ulrich S. Schubert, PhD

    Scientific Advisory Board

    Dr. Schubert is a chemist and professor of organic and macromolecular chemistry at Friedrich Schiller University Jena. He studied chemistry at the universities of Frankfurt am Main and Bayreuth and at Virginia Commonwealth University (Richmond, USA), and received his doctorate from the University of Bayreuth with a joint PhD thesis with the University of South Florida (Tampa, USA). He did postdoctoral research with Jean-Marie Lehn, winner of the 1987 Nobel Prize in Chemistry, and completed his habilitation at the Technical University of Munich. His research focuses on innovative and sustainable polymers with potential applications in the life sciences, such as medicine, and in energy storage and conversion. He was an associate professor at the Center for NanoScience of Ludwig Maximilian University of Munich before receiving a Heisenberg fellowship from the German Research Foundation, which he held at the Technical University of Munich. From 2000 to 2007 he was professor of macromolecular chemistry and nanoscience at Eindhoven University of Technology, and from 2003 to 2014 scientific chairman of the HTE division of the Dutch Polymer Institute. From 2007 to 2010 he held a part-time professorship at Eindhoven while taking up a full professorship of organic and macromolecular chemistry at Friedrich Schiller University Jena.

  • Ulrich Granzer, PhD

    Scientific Advisory Board

    Dr. Granzer qualified as a pharmacist at the University of Marburg in 1984 and went on to doctoral studies, during which he also lectured in pharmaceutical chemistry. In 1988 he served in the German Air Force, reaching the rank of captain with responsibility for drug safety. In 1989 he began his industry career in the Regulatory Affairs department at Glaxo and was appointed Director of Regulatory Affairs in 1993. He then served on the Global Regulatory Board of Glaxo and later Glaxo Wellcome, and during this time led a company-wide reengineering project at Glaxo Germany.

  • Kurt Van Scoik, PhD

    Scientific Advisory Board

    Dr. Van Scoik studied pharmacy and received his doctorate in pharmaceutics from the University of Wisconsin-Madison in 1987. He spent ten years at Abbott Laboratories in the Pharmaceutical Products Division, solving problems in the development of new drugs and new solid dosage forms, including stability, bioavailability and processing, from initial formulation through scale-up. In 1997 he left Abbott as Senior CMC Project Manager to become Senior Director of Pharmaceutical R&D and New Technologies at Schering-Plough Corporation, where he led the launch of more than 60 new products, including tablets, softgels, dermatological products, oral liquids and aerosols.

  • Urs Spitz, PhD

    Scientific Advisory Board

    Dr. Urs Spitz is a life sciences entrepreneur, investor and strategic advisor with extensive experience across pharmaceuticals, biotechnology, diagnostics and life science tools.

Company facts

Headquarters
261 Madison Avenue, 9th Floor, New York, NY 10016, USA
Research and development
Laxxon Medical GmbH, Otto-Schott-Straße 15, 07745 Jena, Germany
Intellectual property
Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.

Frequently asked questions

What does Laxxon Medical do?

Laxxon Medical is a drug development company. It develops oral medicines designed to make treatment simpler for patients, led by an oral GLP-1 RA, and partners with pharma companies on development and licensing.

What is SPID®?

SPID® (Screen Printed Innovative Drug) is a cold-process screen printing platform for oral dosage forms. It prints tablets layer by layer, with layers of 10 to 150 microns, and builds defined internal structures.

What can SPID® do?

SPID® enables tailored release profiles, combinations of several active ingredients in a single dosage form and a defined, heterogeneous distribution of active ingredients within the tablet.

Why an oral GLP-1 RA?

Most GLP-1 RA medicines are peptides, and peptide medicines usually have to be injected because the gastrointestinal tract poses substantial barriers to oral delivery. With LXM.2, Laxxon is developing SPID®-printed oral GLP-1 RA microtablets; Phase 1 is planned for 2027.

Where does the pipeline stand?

Laxxon's focus program is LXM.2, an oral GLP-1 RA, with Phase 1 planned for 2027. LXM.5 for Parkinson's disease is in preparation for Phase 1, with first dosing planned for early 2027. LXM.8, a partner program, completed Phase 1 in August 2025. Six further programs are in preclinical development.

How large is the patent portfolio?

Including in-licensed rights, Laxxon's portfolio comprises more than 230 patents and patent applications, with terms potentially extending into 2046 (company figures, as of November 2026).

What rights does Laxxon hold to SPID®?

Laxxon holds its own patents, such as US 11,419,824 B2. Since 2017, Laxxon has held the exclusive worldwide license from Exentis Group AG and Exentis Knowledge GmbH for pharmaceutical applications of the technology behind SPID®.

Is Laxxon a contract manufacturer?

No. Laxxon is a drug development company and does not offer contract manufacturing. It prints development batches at its research and development site in Jena, Germany; clinical-scale cGMP manufacturing for its programs is being established with CDMO partner Adare Pharma Solutions in Pessano (Milan), Italy.

Which regulatory pathways does Laxxon use?

Laxxon develops its programs for the FDA 505(b)(2) pathway in the US and the hybrid application under Article 10(3) of Directive 2001/83/EC in the EU.

How can a pharma company work with Laxxon?

Through licensing or co-development of Laxxon's pipeline assets, development projects with SPID®, or lifecycle management of established products.

Is Laxxon publicly listed?

No. Laxxon Medical Corp. is privately held.

Who owns Laxxon Medical?

Laxxon Medical Corp. is an independent, privately held company headquartered in New York. It is not a subsidiary of Xlife Sciences AG or of any other company, and Xlife Sciences AG holds no shares in Laxxon.

How is Laxxon financed?

Since its founding in 2017, Laxxon has been financed by private and institutional investors. Shareholders receive a company update twice a year. Qualified investors can request company documents from investor relations.